PMID- 26848773
OWN - NLM
STAT- MEDLINE
DCOM- 20180124
LR  - 20190221
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 16
DP  - 2016 Apr 19
TI  - Long-term prognostic implications and therapeutic target role of hexokinase II in 
      patients with nasopharyngeal carcinoma.
PG  - 21287-97
LID - 10.18632/oncotarget.7116 [doi]
AB  - Tumor cells preferentially use anaerobic glycolysis rather than oxidative 
      phosphorylation to generate energy. Hexokinase II (HK-II) is necessary for 
      anaerobic glycolysis and displays aberrant expression in malignant cells. The 
      current study aimed to evaluate the role of HK-II in the survival and biological 
      function of nasopharyngeal carcinoma (NPC). Our study demonstrated that high 
      expression of HK-II was associated with poor survival outcomes in NPC patients. 
      When using 3-BrOP (an HK-II inhibitor) to repress glycolysis, cell proliferation 
      and invasion were attenuated, accompanied by the induction of apoptosis and cell 
      cycle arrest at the G1 stage. Furthermore, 3-BrOP synergized with cisplatin (DDP) 
      to induce NPC cell death. Collectively, we provided that the aberrant expression 
      of HK-II was associated with the malignant phenotype of NPC. A combined treatment 
      modality that targets glycolysis with DDP holds promise for the treatment of NPC 
      patients.
FAU - Zhang, Meng-Xia
AU  - Zhang MX
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
FAU - Hua, Yi-Jun
AU  - Hua YJ
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
FAU - Wang, Hai-Yun
AU  - Wang HY
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P. R. China.
FAU - Zhou, Ling
AU  - Zhou L
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
FAU - Mai, Hai-Qiang
AU  - Mai HQ
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
FAU - Guo, Xiang
AU  - Guo X
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
FAU - Zhao, Chong
AU  - Zhao C
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, 
      Guangdong 510060, P. R. China.
FAU - Huang, Wen-Lin
AU  - Huang WL
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
FAU - Hong, Ming-Huang
AU  - Hong MH
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
FAU - Chen, Ming-Yuan
AU  - Chen MY
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
AD  - Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 
      Guangzhou, Guangdong 510060, P. R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (3-bromo-2-oxopropionate-1-propyl ester)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Hydrocarbons, Brominated)
RN  - 0 (Propionates)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis/drug effects
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma/drug therapy/*enzymology/pathology
MH  - Cell Cycle/drug effects
MH  - Cell Movement/drug effects
MH  - Cell Proliferation
MH  - Female
MH  - Hexokinase/*antagonists & inhibitors/metabolism
MH  - Humans
MH  - Hydrocarbons, Brominated/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Carcinoma
MH  - Nasopharyngeal Neoplasms/drug therapy/*enzymology/pathology
MH  - Oxidative Phosphorylation
MH  - Prognosis
MH  - Propionates/*pharmacology
MH  - Signal Transduction
MH  - Survival Rate
MH  - Tumor Cells, Cultured
MH  - Young Adult
PMC - PMC5008285
OTO - NOTNLM
OT  - 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP)
OT  - hexokinase II (HK-II)
OT  - nasopharyngeal carcinoma (NPC)
OT  - survival
OT  - therapeutic target
COIS- None.
EDAT- 2016/02/06 06:00
MHDA- 2018/01/25 06:00
PMCR- 2016/04/19
CRDT- 2016/02/06 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2016/01/18 00:00 [accepted]
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2018/01/25 06:00 [medline]
PHST- 2016/04/19 00:00 [pmc-release]
AID - 7116 [pii]
AID - 10.18632/oncotarget.7116 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Apr 19;7(16):21287-97. doi: 10.18632/oncotarget.7116.